Osteopenia in cerebral palsy.
The bone mineral density of the lumbar spine was assessed in nine non-ambulant children with cerebral palsy combined with measurements of serum 25-hydroxyvitamin D, parathyroid hormone, and urinary calcium excretion. Three children with recurrent fractures received treatment with bisphosphonates for periods ranging from 12-18 months. All the children demonstrated a severe reduction in bone mineral density even when allowance was made for their body weight. There were no consistent abnormalities of vitamin D or parathyroid hormone status. Three children had gross hypercalciuria. Each of the children treated with bisphosphonates demonstrated an increment in bone density ranging from 20-40% with no apparent adverse effects.
Shaw
N J
NJ
Institute of Child Health, Alder Hey Children's Hospital, Liverpool.
White
C P
CP
Fraser
W D
WD
Rosenbloom
L
L
D015652:25-Hydroxyvitamin D 2 / Q000097:blood; D000293:Adolescent; D015519:Bone Density; D001851:Bone Diseases, Metabolic / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism; D002112:Calcifediol / Q000097:blood; D002118:Calcium / Q000652:urine; D002547:Cerebral Palsy / Q000150:complications* / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control; D006801:Humans; D008159:Lumbar Vertebrae / Q000737:chemistry; D008297:Male; D010281:Parathyroid Hormone / Q000097:blood
D004164:Diphosphonates; D010281:Parathyroid Hormone; D015652:25-Hydroxyvitamin D 2; D002112:Calcifediol; D002118:Calcium